Jacob Johnson
Stock Analyst at Stephens & Co.
(2.83)
# 1,630
Out of 5,131 analysts
78
Total ratings
45.76%
Success rate
8.62%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $256.82 | -6.55% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $5.40 | +11.11% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.56 | -20.63% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $37.92 | +58.23% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $238.37 | +32.15% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $618.86 | +9.88% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $166.82 | +1.91% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.19 | +19.33% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.43 | +669.23% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $21.06 | +80.44% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $10.55 | +61.14% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.06 | +21.36% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $65.70 | +32.42% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $275.52 | +41.55% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $13.16 | +36.78% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.64 | +265.85% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $24.86 | +16.65% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $206.54 | -37.06% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $220.91 | +70.66% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $256.82
Upside: -6.55%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.40
Upside: +11.11%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.56
Upside: -20.63%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $37.92
Upside: +58.23%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $238.37
Upside: +32.15%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $618.86
Upside: +9.88%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $166.82
Upside: +1.91%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.19
Upside: +19.33%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.43
Upside: +669.23%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $21.06
Upside: +80.44%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $10.55
Upside: +61.14%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.06
Upside: +21.36%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $65.70
Upside: +32.42%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $275.52
Upside: +41.55%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $13.16
Upside: +36.78%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.64
Upside: +265.85%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $24.86
Upside: +16.65%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $206.54
Upside: -37.06%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $220.91
Upside: +70.66%